论文部分内容阅读
目的:研究先天性卵巢功能衰竭(特纳综合征)患者的骨质状况及以雌激素为主的治疗对患者骨量的影响。从而找到阻止骨量丢失的方法。方法:分析我院2006年3月—2014年3月8年,青海高原地区先天性卵巢功能衰竭患者21例,对其进行骨密度监测并与同期正常同龄女性相对比;给予患者激素治疗后再次与对照组给予治疗前骨量进行对照,并对患者骨量的变化因素进行分析。结果:特纳患者的骨密度明显低于正常同龄女性(P<0.01);激素治疗前后骨量均值对比无显著差异(P>0.05),雌激素治疗后患者骨密度与正常人群有显著差异(P<0.01);骨量与未治疗前相仿;治疗后临床不适症状明显减轻(P<0.05)。结论:高原地区特纳综合征的骨密度明显低于正常同龄女性,骨质疏松患者明显增加,骨折风险增加;雌激素治疗对维持骨量有益,但骨量增加并不明显,疑似与激素治疗开始的年龄有关;多数患者虽经治疗,其终身仍将处于低骨量状态,骨折风险高;雌激素治疗有利于患者全身症状的改善。
OBJECTIVE: To investigate the effects of estrogen-based therapy on bone mass in patients with congenital ovarian failure (Turner syndrome). To find a way to prevent bone loss. Methods: In our hospital from March 2006 to March 2014 8 years, 21 cases of congenital ovarian failure in Qinghai Plateau, bone mineral density was monitored and compared with the same age women of same age; patients given hormone therapy again after The control group was given pre-treatment bone mass comparison, and analysis of changes in the patient’s bone mass. Results: The BMD of Turner patients was significantly lower than that of normal females (P <0.01). There was no significant difference in BMD before and after hormone treatment (P> 0.05). There was significant difference between the two groups P <0.01). The bone mass was similar to that before treatment; the clinical symptoms were relieved after treatment (P <0.05). CONCLUSIONS: The BMD of Turner syndrome in the plateau is significantly lower than that in normal females. The patients with osteoporosis are significantly increased and the risk of fractures is increased. Estrogen therapy is beneficial to maintain the bone mass, but the bone mass increase is not obvious. Susceptibility and hormone therapy The beginning of the age-related; the majority of patients despite treatment, the life-long will remain in a low bone mass state, high risk of fracture; estrogen treatment is conducive to the improvement of systemic symptoms.